Koers Dynavax Technologies Corporation Nasdaq
Aandelen
US2681581029
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 285 mln. 262 mln. | Omzet 2025 * | 350 mln. 322 mln. | Marktkapitalisatie | 1,48 mld. 1,36 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 18 mln. 16,56 mln. | Nettowinst (verlies) 2025 * | 48 mln. 44,15 mln. | EV/omzet 2024 * | 3,23 x |
Nettoliquiditeiten 2024 * | 556 mln. 511 mln. | Nettoliquiditeiten 2025 * | 683 mln. 628 mln. | EV/omzet 2025 * | 2,27 x |
K/w-verhouding 2024 * |
70,5
x | K/w-verhouding 2025 * |
31,3
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,69% |
Recentste transcriptie over Dynavax Technologies Corporation
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ryan Spencer
CEO | Chief Executive Officer | 46 | 01-01-05 |
David Novack
PSD | President | 62 | 25-03-13 |
Patricia Novy
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Francis Cano
BRD | Director/Board Member | 79 | 03-11-09 |
Peggy Phillips
BRD | Director/Board Member | 70 | 01-08-06 |
Dan Kisner
BRD | Director/Board Member | 77 | 22-07-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 114 mld. | |
+11,84% | 104 mld. | |
-14,15% | 22,41 mld. | |
-1,05% | 22,28 mld. | |
-5,29% | 19,07 mld. | |
-38,29% | 18 mld. | |
-4,16% | 17,89 mld. | |
+7,99% | 14,28 mld. | |
+36,24% | 12,55 mld. |
- Beurs
- Aandelen
- Koers DVAX
- Koers